CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The BIOMAGSCAR project develops a biodegradable magnetized stent that utilizes biological therapy to regenerate the coronary artery wall. By attracting progenitor cells, it aims to reduce complications like restenosis and thrombosis, improving patient outcomes in cardiovascular treatments.
By 2010 1.5 million stents per year will be deployed in Europe.
Although outcome for patients has improved, stents still fail because of the occurrence of restenosis and thrombosis at the site of implantation.
While drug eluting stents have helped to reduce the problem of restenosis, neointimal proliferation causing restenosis can still occur.
Additional concerns exist regarding drug eluting stents as there appears to be a small but real increase in late and very late stent thrombosis, particula…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, WINSEN
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
United Kingdom, CHINNOR OXFORDSHIRE
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITY OF EASTERN FINLAND (UEF)
Finland, KUOPIO
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, LONDON
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
